Get the Stockscreener App
1.18
1.72%
0.02
After Hours:
1.15
-0.03
-2.54%
Heron Therapeutics Inc stock is traded at $1.18, with a volume of 4.92M.
It is up +1.72% in the last 24 hours and down -10.61% over the past month.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
See More
Previous Close:
$1.16
Open:
$1.18
24h Volume:
4.92M
Relative Volume:
2.60
Market Cap:
$216.31M
Revenue:
$137.74M
Net Income/Loss:
$-27.97M
P/E Ratio:
-7.375
EPS:
-0.16
Net Cash Flow:
$-9.61M
1W Performance:
+0.00%
1M Performance:
-10.61%
6M Performance:
-48.92%
1Y Performance:
-33.71%
1-Day Range:
$1.09
$1.28
1-Week Range:
$1.09
$1.28
52-Week Range:
$1.04
$2.68
Heron Therapeutics Inc Stock (HRTX) Company Profile
Name
Heron Therapeutics Inc
Sector
Industry
Phone
(858) 251-4400
Address
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
Compare HRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HRTX
Heron Therapeutics Inc
|
1.18 | 212.64M | 137.74M | -27.97M | -9.61M | -0.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-09-25 | Initiated | H.C. Wainwright | Buy |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-23-24 | Initiated | CapitalOne | Overweight |
| Mar-13-24 | Reiterated | Needham | Buy |
| May-27-20 | Initiated | Guggenheim | Buy |
| Feb-20-20 | Reiterated | Needham | Buy |
| Jan-16-19 | Reiterated | Needham | Buy |
| Apr-05-18 | Initiated | Evercore ISI | Outperform |
| Mar-19-18 | Reiterated | Mizuho | Buy |
| Mar-01-18 | Reiterated | Needham | Buy |
| Jan-03-18 | Initiated | Leerink Partners | Outperform |
| Sep-27-17 | Initiated | Northland Capital | Outperform |
| Feb-27-17 | Initiated | Needham | Buy |
| Oct-26-16 | Initiated | Aegis Capital | Buy |
| Sep-06-16 | Resumed | Lake Street | Buy |
| May-03-16 | Initiated | Cantor Fitzgerald | Buy |
| Dec-10-15 | Initiated | Lake Street | Buy |
| Sep-23-15 | Reiterated | Leerink Partners | Outperform |
| Sep-02-15 | Initiated | BofA/Merrill | Buy |
| Aug-03-15 | Reiterated | Brean Capital | Buy |
| Jun-30-15 | Reiterated | JMP Securities | Mkt Outperform |
| Jun-19-15 | Reiterated | Leerink Partners | Outperform |
| Aug-07-14 | Initiated | Noble Financial | Buy |
View All
Heron Therapeutics Inc Stock (HRTX) Latest News
Ranking Heron Therapeutics Inc. among high performing stocks via toolsLong Setup & Safe Capital Growth Stock Tips - newser.com
Heron Therapeutics Inc. stock chart pattern explainedEarnings Risk Summary & Reliable Price Breakout Signals - newser.com
Can Heron Therapeutics Inc. (AXD2) stock deliver consistent EPS growthMarket Performance Report & AI Powered Market Entry Strategies - newser.com
What analyst consensus says on Heron Therapeutics Inc. stockJuly 2025 Market Mood & Accurate Intraday Trade Tips - newser.com
Can trapped investors hope for a rebound in Heron Therapeutics Inc.2025 Biggest Moves & Daily Risk Controlled Trade Plans - newser.com
Heron Therapeutics Inc. stock prediction for this week2025 Historical Comparison & Consistent Growth Stock Picks - newser.com
Why Heron Therapeutics Inc. (AXD2) stock could rally strongly2025 Performance Recap & Accurate Entry and Exit Point Alerts - newser.com
Will Heron Therapeutics Inc. stock attract more institutional investorsInsider Selling & Reliable Breakout Forecasts - newser.com
Tools to monitor Heron Therapeutics Inc. recovery probabilityWeekly Gains Report & Risk Controlled Swing Alerts - newser.com
Should you wait for a breakout in Heron Therapeutics Inc.Portfolio Return Report & Entry and Exit Point Strategies - newser.com
Sentiment analysis tools applied to Heron Therapeutics Inc.2025 Price Targets & Risk Controlled Daily Plans - newser.com
Is Heron Therapeutics Inc. (AXD2) stock inflation resilient2025 Top Gainers & Reliable Volume Spike Trade Alerts - newser.com
Heron Therapeutics Inc. stock daily chart insightsWeekly Trade Analysis & Reliable Entry Point Alerts - newser.com
Can Heron Therapeutics Inc. recover in the next quarterJuly 2025 News Drivers & Fast Entry Momentum Alerts - newser.com
What MACD and RSI say about Heron Therapeutics Inc.Weekly Trade Report & Free Safe Capital Growth Stock Tips - newser.com
Developing predictive dashboards with Heron Therapeutics Inc. dataTrade Ideas & Verified Technical Signals - newser.com
Can Heron Therapeutics Inc. stock weather global recessionJuly 2025 Decliners & Verified Momentum Stock Ideas - newser.com
Detecting price anomalies in Heron Therapeutics Inc. with AI2025 Market WrapUp & Safe Entry Point Identification - newser.com
Will Heron Therapeutics Inc. stock outperform Nasdaq indexTrade Entry Report & Fast Moving Trade Plans - newser.com
Why Heron Therapeutics Inc. (AXD2) stock attracts wealthy investorsJobs Report & Growth Oriented Trading Recommendations - newser.com
Heron Therapeutics Appoints Thomas Cusack to Board - The Globe and Mail
Published on: 2025-10-30 01:17:43 - newser.com
Heron Therapeutics, Inc. Appoints Thomas Cusack to Board of Directors - Quiver Quantitative
Heron Therapeutics Inc Stock (HRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Heron Therapeutics Inc Stock (HRTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Morgan Adam | Director |
Aug 08 '25 |
Buy |
1.50 |
1,766,546 |
2,649,819 |
8,753,290 |
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):